Bartonellosis market seen reaching $2.24 billion by 2030

The bartonellosis market is projected to grow from $1.3 billion in 2025 to $2.24 billion by 2030 as demand rises for faster diagnostics, earlier treatment and broader infectious disease care. North America held the largest share in 2025, while zoonotic disease growth and new testing tools are expected to drive future expansion.

Why it matters: - Bartonellosis is a bacterial infection that can affect the skin, lymphatic system and internal organs. - Faster diagnosis and timely antibiotic treatment can reduce the risk of serious systemic complications. - The market outlook reflects broader demand for better tools to detect and treat zoonotic diseases that spread from animals to humans.

What happened: - The bartonellosis market is expected to increase from $1.3 billion in 2025 to $1.46 billion in 2026. - The market is forecast to reach $2.24 billion by 2030. - The projected growth rate is 11.7% from 2025 to 2026 and 11.3% over the forecast period through 2030. - The Business Research Company released the market outlook on Nov. 4, 2026, from London. - The report includes a free sample and a full version available through the company’s website: Download the sample report and View the full report.

The details: - Historical growth has been supported by more cat scratch disease cases, better infectious disease diagnostics, wider antibiotic availability, more hospital diagnostic laboratories and higher clinician awareness of Bartonella infections. - Future growth is linked to rapid diagnostic assays, earlier intervention for systemic infection, more specialized infectious disease treatment centers, precision antibiotic therapies and higher investment in zoonotic disease research. - Bartonellosis growth is being driven in part by rising zoonotic disease incidence, including infections spread by fleas, ticks and lice. - Human-animal contact, deforestation, global travel and cross-species pathogen spread are adding pressure to public health systems. - In December 2024, the European Food Safety Authority and the European Centre for Disease Prevention and Control reported that human campylobacteriosis cases rose 4.3% to 148,181 from 139,225 in 2022. - The same report said salmonellosis cases increased 16.9% to 77,486 from 65,478 in 2022.

Between the lines: - The market forecast suggests bartonellosis is being treated less as a niche infection and more as part of a larger zoonotic disease response. - North America held the largest share in 2025, which points to the advantage of more advanced healthcare infrastructure and higher disease awareness. - Other growth regions include Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report’s emphasis on market attractiveness scoring, TAM analysis and hotspot mapping signals stronger investor and strategy interest in the category.

What's next: - Growth will likely depend on how quickly diagnostic testing improves and how widely early treatment protocols are adopted. - Expansion in specialized infectious disease centers and continued research into zoonotic transmission could support demand through 2030. - The report says future editions will include updated graphics, dashboards, company scoring matrices and trend analysis tools.